<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784277</url>
  </required_header>
  <id_info>
    <org_study_id>CR014326</org_study_id>
    <secondary_id>KF5503/41</secondary_id>
    <nct_id>NCT00784277</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Arm, Multicenter Study in Subjects With End-Stage Joint Disease to Compare the Frequency of Constipation Symptoms in SubjectsTreated With Tapentadol IR and Oxycodone IR Using a Bowel Function Patient Diary</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gr√ºnenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare bowel function/constipation that occurs during
      tapentadol treatment with that occuring during oxycodone treatment, as measured by the
      frequency of spontaneous bowel movements per week. The frequency of spontaneous bowel
      movements will be determined from a Bowel Function Patient Diary completed by the enrolled
      sujbects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic pain from end-stage degenerative joint disease is often moderate to severe in
      intensity and results in a relatively constant level of pain requiring continuous pain relief
      medication. Despite available pain relief medications, 60% to 80% of subjects suffering from
      chronic pain are currently inadequately treated. Opioid pain medications are central to the
      effective treatment of moderate to severe pain. However, opioid therapy is frequently
      complicated by side effects. Constipation is one of the most commonly reported side effects
      and most debilitating. An opioid medication that provides pain relief with a reduced
      incidence of constipation symptoms would improve the capability of subjects to stay on
      medication to achieve the long-term relief they need. This is a randomized, double-blind,
      placebo- and active-controlled, parallel-arm, multicenter study with 4 treatment groups of
      subjects who have moderate to severe chronic pain from end-stage degenerative joint disease
      of the hip or knee and who are candidates for primary total or partial joint replacement. The
      study consists of 3 periods: a pretreatment period (a 14-day screening for study eligibility
      and a 7-day washout of any previously taken opioid medication), a double-blind treatment
      period (a 14-day IR treatment phase followed by a 28-day ER treatment phase), and a follow-up
      period (1 study-site visit within 4 days after the last dose of study drug is taken and 1
      telephone contact within 10 to 14 days after the last dose of study drug is taken). On Day 1
      of the IR treatment phase, patients will be randomly assigned to 1 of 4 possible treatment
      groups to receive 50 mg CG5503 IR, 75 mg CG5503 IR, 10 mg oxycodone IR, or placebo daily
      every 4 to 6 hours. At the beginning of the ER treatment phase, patients' study drugs will be
      transitioned to the ER form (by conversion from the IR to approximate equivalent total daily
      doses of the ER form) of their randomly assigned study drug of tapentadol ER, oxycodone CR,
      or placebo. The ER study drugs will be taken every 12 hours b.i.d. Dosages will be
      adjustable, with the study site personnel oversight, to ensure adequate pain relief is
      provided. Beginning with the washout period, patients will be given hand-held computer
      diaries in which to record their pain intensity, pain relief, bowel movement information, and
      answer questions on any nausea or vomiting that may occur. In addition, patients will write
      down the times and dosages of all medications they take during the study in a medication
      diary. Safety and tolerability will be assessed using physical examination, monitoring of
      adverse events, clinical and laboratory measures, and 12 lead ECG results. The first study
      hypothesis is that both tapentadol IR dosages are more effective than placebo in relieving
      pain based on the SPID score recorded by the patients over the first 5 days of the study. The
      second study hypothesis is that the Bowel Function Patient Diary results for both tapentadol
      IR dosages demonstrate improved tolerability compared to oxycodone IR 10 mg, based on the
      number of spontaneous bowel movements per week over the first 2 weeks of the study. In the IR
      treatment phase, each patient will take CG5503 IR 50 mg, CG5503 IR 75 mg, oxycodone IR 10 mg,
      or placebo orally every 4 to 6 hours for 14 days. In the ER treatment phase, dosages of the
      IR treatment groups will be converted to approximately equivalent dosages of the ER form of
      the assigned study drug: tapentadol ER, oxycodone CR, or placebo. Dosages may range from 100
      to 500 mg/day of tapentadol ER and 20 to 60 mg/day of oxycodone CR taken orally 2x daily for
      28 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-Day Sum of Pain Intensity Difference (SPID5)</measure>
    <time_frame>Day 1 to Day 5</time_frame>
    <description>SPID5 was calculated as the weighted (weights is taken as the number of hours elapsed since the previous measurement) sum of the PID collected up to 5 days. Pain intensity (PI) score is calculated as the average PI over the past 12 hours using an 11-point (0 to 10) numerical rating scale (NRS) where &quot;0&quot; is no pain and &quot;10&quot; is pain as bad as you can imagine. The difference between baseline PI at the qualifying period and current PI is pain intensity difference (PID).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spontaneous Bowel Movements Per Week (SBMs/Week)</measure>
    <time_frame>Week 1 to Week 2</time_frame>
    <description>The number of SBM over the 14-day IR treatment phase was determined from the Bowel Function Patient Diary and factored to enable a per week value to be used. An SBM is defined as any BM that has occurred without the use of a laxative, enema, suppository, or manual manipulation within the previous 24 hours.</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">597</enrollment>
  <condition>Joint Diseases</condition>
  <condition>Arthritis</condition>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tapentadol IR (CG5503) 50mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tapentadol IR (CG5503) 75mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oxycodone IR 10mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>004</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 1 capsule for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tapentadol ER (CG5503) flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>006</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oxycodone CR flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>007</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo Tablets and capsules 2 x a day for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxycodone CR</intervention_name>
    <description>flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)</description>
    <arm_group_label>006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxycodone IR</intervention_name>
    <description>10mg for 14 days</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tapentadol ER (CG5503)</intervention_name>
    <description>flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)</description>
    <arm_group_label>005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tapentadol IR (CG5503)</intervention_name>
    <description>50mg for 14 days</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tapentadol IR (CG5503)</intervention_name>
    <description>75mg for 14 days</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 capsule for 14 days</description>
    <arm_group_label>004</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Tablets and capsules 2 x a day for 28 days</description>
    <arm_group_label>007</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical diagnosis of osteoarthritis of the hip or knee

          -  End-stage degenerative joint disease

          -  Eligibility for primary unilateral total or partial joint replacement surgery

          -  Pain level moderate to severe and at such a level as to require daily doses of an
             opioid analgesic medication

        Exclusion Criteria:

          -  Has a life-long history of seizure disorder or epilepsy

          -  Had any of the following within the preceding 1 year: mild or moderate traumatic brain
             injury, stroke, transient ischemic attack, or brain neoplasm

          -  Had a severe traumatic brain injury within 15 years of screening (consisting of one or
             more of the following: brain contusion, intracranial hematoma, either unconsciousness
             or post traumatic amnesia lasting for more than 24 hours)

          -  Joint pain not associated with gout, fibromyalgia, rheumatoid arthritis, other
             autoimmune disease

          -  History of alcohol or drug abuse

          -  chronic hepatitis B and C or HIV, active hepatitis B and C within 3 months

          -  Severely impaired renal function or moderately to severely impaired hepatic function

          -  History of cancer within past 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2008</study_first_submitted>
  <study_first_submitted_qc>October 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2008</study_first_posted>
  <results_first_submitted>July 22, 2010</results_first_submitted>
  <results_first_submitted_qc>January 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 13, 2012</results_first_posted>
  <last_update_submitted>January 9, 2012</last_update_submitted>
  <last_update_submitted_qc>January 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2012</last_update_posted>
  <responsible_party>
    <name_title>Senior Director, Clinical Leader</name_title>
    <organization>Johnson &amp; Johnson Pharmaceutical Research and Development, L.L.C.</organization>
  </responsible_party>
  <keyword>Pain medication</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Joint pain</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Analgesics</keyword>
  <keyword>tapentadol</keyword>
  <keyword>CG5503</keyword>
  <keyword>Nucynta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1000 participants were screened, 598 were randomized, 596 participants received medication in the first part of the double-blind treatment period (IR treatment phase). A total of 463 participants received medication in the second part of the double-blind treatment period (ER treatment phase).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>IR Treatment : 1 capsule for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Tapentadol 50 mg</title>
          <description>IR Treatment : 50mg for 14 days</description>
        </group>
        <group group_id="P3">
          <title>Tapentadol 75 mg</title>
          <description>IR Treatment : 75mg for 14 days</description>
        </group>
        <group group_id="P4">
          <title>Oxycodone</title>
          <description>IR Treatment : 10mg for 14 days</description>
        </group>
        <group group_id="P5">
          <title>Placebo ER</title>
          <description>ER Treatment : Tablets and capsules 2 x a day for 28 days</description>
        </group>
        <group group_id="P6">
          <title>Tapentadol ER</title>
          <description>ER Treatment : flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)</description>
        </group>
        <group group_id="P7">
          <title>Oxycodone CR</title>
          <description>ER Treatment : flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>IR Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="154"/>
                <participants group_id="P4" count="143"/>
                <participants group_id="P5" count="0">&quot;0&quot; in ER column indicates this reporting group is not relevant to IR phase.</participants>
                <participants group_id="P6" count="0">&quot;0&quot; in ER column indicates this reporting group is not relevant to IR phase.</participants>
                <participants group_id="P7" count="0">&quot;0&quot; in ER column indicates this reporting group is not relevant to IR phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="126"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Resolution Of Pain</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>ER Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">&quot;0&quot; in IR column indicates this reporting group is not relevant to ER phase.</participants>
                <participants group_id="P2" count="0">&quot;0&quot; in IR column indicates this reporting group is not relevant to ER phase.</participants>
                <participants group_id="P3" count="0">&quot;0&quot; in IR column indicates this reporting group is not relevant to ER phase.</participants>
                <participants group_id="P4" count="0">&quot;0&quot; in IR column indicates this reporting group is not relevant to ER phase.</participants>
                <participants group_id="P5" count="122">10 participants who had completed IR treatment have not taken any ER treatment.</participants>
                <participants group_id="P6" count="250">10 participants who had completed IR treatment have not taken any ER treatment.</participants>
                <participants group_id="P7" count="91">9 participants who had completed IR treatment have not taken any ER treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="113"/>
                <participants group_id="P6" count="226"/>
                <participants group_id="P7" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Medication Non-Compliant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>IR Treatment : 1 capsule for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Tapentadol 50 mg</title>
          <description>IR Treatment : 50mg capsule for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Tapentadol 75 mg</title>
          <description>IR Treatment : 75mg capsule for 14 days</description>
        </group>
        <group group_id="B4">
          <title>Oxycodone</title>
          <description>IR Treatment : 10mg capsule for 14 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
            <count group_id="B2" value="151"/>
            <count group_id="B3" value="154"/>
            <count group_id="B4" value="143"/>
            <count group_id="B5" value="596"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="109"/>
                    <measurement group_id="B5" value="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="9.57"/>
                    <measurement group_id="B2" value="58" spread="9.47"/>
                    <measurement group_id="B3" value="58.4" spread="7.66"/>
                    <measurement group_id="B4" value="59.4" spread="7.94"/>
                    <measurement group_id="B5" value="58.7" spread="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region Enroll</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>USA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="109"/>
                    <measurement group_id="B5" value="457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>5-Day Sum of Pain Intensity Difference (SPID5)</title>
        <description>SPID5 was calculated as the weighted (weights is taken as the number of hours elapsed since the previous measurement) sum of the PID collected up to 5 days. Pain intensity (PI) score is calculated as the average PI over the past 12 hours using an 11-point (0 to 10) numerical rating scale (NRS) where ‚Äú0‚Äù is no pain and ‚Äú10‚Äù is pain as bad as you can imagine. The difference between baseline PI at the qualifying period and current PI is pain intensity difference (PID).</description>
        <time_frame>Day 1 to Day 5</time_frame>
        <population>Intention To Treat (ITT) population : One participant who has been treated is not included in the ITT population as no baseline pain assessment was available (Arm: Tapentadol 50 mg).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>IR Treatment : 1 capsule for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Tapentadol 50 mg</title>
            <description>IR Treatment : 50mg capsule for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Tapentadol 75 mg</title>
            <description>IR Treatment : 75mg capsule for 14 days</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone</title>
            <description>IR Treatment : 10mg capsule for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>5-Day Sum of Pain Intensity Difference (SPID5)</title>
          <description>SPID5 was calculated as the weighted (weights is taken as the number of hours elapsed since the previous measurement) sum of the PID collected up to 5 days. Pain intensity (PI) score is calculated as the average PI over the past 12 hours using an 11-point (0 to 10) numerical rating scale (NRS) where ‚Äú0‚Äù is no pain and ‚Äú10‚Äù is pain as bad as you can imagine. The difference between baseline PI at the qualifying period and current PI is pain intensity difference (PID).</description>
          <population>Intention To Treat (ITT) population : One participant who has been treated is not included in the ITT population as no baseline pain assessment was available (Arm: Tapentadol 50 mg).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" spread="134.73"/>
                    <measurement group_id="O2" value="153.1" spread="184.07"/>
                    <measurement group_id="O3" value="161.8" spread="187.31"/>
                    <measurement group_id="O4" value="218.4" spread="208.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P-value is adjusted for multiplicity for comparison against placebo using Hochberg's test.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The model includes treatment and pooled center as factors and baseline pain intensity score as covariate.</method_desc>
            <param_type>Difference in Least-Squares Means</param_type>
            <param_value>55.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>20.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>15.11</ci_lower_limit>
            <ci_upper_limit>95.13</ci_upper_limit>
            <estimate_desc>The 95% confidence interval is unadjusted for multiplicity.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value is adjusted for multiplicity for comparison against placebo using Hochberg's test.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The model includes treatment and pooled center as factors and baseline pain intensity score as covariate.</method_desc>
            <param_type>Difference in Least-Squares Means</param_type>
            <param_value>63.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>20.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>23.67</ci_lower_limit>
            <ci_upper_limit>103.13</ci_upper_limit>
            <estimate_desc>The 95% confidence interval is unadjusted for multiplicity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Spontaneous Bowel Movements Per Week (SBMs/Week)</title>
        <description>The number of SBM over the 14-day IR treatment phase was determined from the Bowel Function Patient Diary and factored to enable a per week value to be used. An SBM is defined as any BM that has occurred without the use of a laxative, enema, suppository, or manual manipulation within the previous 24 hours.</description>
        <time_frame>Week 1 to Week 2</time_frame>
        <population>Intention To Treat (ITT) population : One participant who has been treated is not included in the ITT population as no baseline pain assessment was available (Arm: Tapentadol 50 mg).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>IR Treatment : 1 capsule for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Tapentadol 50 mg</title>
            <description>IR Treatment : 50mg capsule for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Tapentadol 75 mg</title>
            <description>IR Treatment : 75mg capsule for 14 days</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone</title>
            <description>IR Treatment : 10mg capsule for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Spontaneous Bowel Movements Per Week (SBMs/Week)</title>
          <description>The number of SBM over the 14-day IR treatment phase was determined from the Bowel Function Patient Diary and factored to enable a per week value to be used. An SBM is defined as any BM that has occurred without the use of a laxative, enema, suppository, or manual manipulation within the previous 24 hours.</description>
          <population>Intention To Treat (ITT) population : One participant who has been treated is not included in the ITT population as no baseline pain assessment was available (Arm: Tapentadol 50 mg).</population>
          <units>number of stools/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="5.16"/>
                    <measurement group_id="O2" value="9.0" spread="4.04"/>
                    <measurement group_id="O3" value="8.6" spread="4.65"/>
                    <measurement group_id="O4" value="6.7" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is adjusted for multiplicity for comparison against Oxycodone using Hochberg's test.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The model includes treatment and pooled center as factors and baseline value as covariate.</method_desc>
            <param_type>Difference in Least-Squares Means</param_type>
            <param_value>3.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.22</ci_lower_limit>
            <ci_upper_limit>4.01</ci_upper_limit>
            <estimate_desc>The 95% confidence interval is unadjusted for multiplicity.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is adjusted for multiplicity for comparison against Oxycodone using Hochberg's test.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The model includes treatment and pooled center as factors and baseline value as covariate.</method_desc>
            <param_type>Difference in Least-Squares Means</param_type>
            <param_value>2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.34</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
            <estimate_desc>The 95% confidence interval is unadjusted for multiplicity.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is adjusted for multiplicity for comparison against Oxycodone using Hochberg's test.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The model includes treatment and pooled center as factors and baseline value as covariate.</method_desc>
            <param_type>Difference in Least-Squares Means</param_type>
            <param_value>1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>2.50</ci_upper_limit>
            <estimate_desc>The 95% confidence interval is unadjusted for multiplicity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only participants who had at least one of the TEAEs listed in the Other (non Serious) AE table are included in the Total no. participants with Non-Serious Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>IR Treatment : 1 capsule for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Tapentadol 50 mg</title>
          <description>IR Treatment : 50mg for 14 days</description>
        </group>
        <group group_id="E3">
          <title>Tapentadol 75 mg</title>
          <description>IR Treatment : 75mg for 14 days</description>
        </group>
        <group group_id="E4">
          <title>Oxycodone</title>
          <description>IR Treatment : 10mg for 14 days</description>
        </group>
        <group group_id="E5">
          <title>Placebo ER</title>
          <description>ER Treatment : Tablets and capsules 2 x a day for 28 days</description>
        </group>
        <group group_id="E6">
          <title>Tapentadol ER</title>
          <description>ER Treatment : flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)</description>
        </group>
        <group group_id="E7">
          <title>Oxycodone CR</title>
          <description>ER Treatment : flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="88" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="98" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="80" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="36" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, Clinical Leader</name_or_title>
      <organization>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</organization>
      <phone>609-730-4537</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

